High serum C-reactive protein level predicts mortality in patients with stage 3 chronic kidney disease or higher and diabetic foot infections  by Lee, Sang Jin et al.
Kidney Res Clin Pract 32 (2013) 171–176journal homepage: http://www.krcp-ksn.com
Kidney Research and Clinical Practice2211-91
license
http://d
n Corre
Interna
Seohyu
E-mailContents lists available at ScienceDirectOriginal ArticleHigh serum C-reactive protein level predicts mortality in patients with
stage 3 chronic kidney disease or higher and diabetic foot infectionsSang Jin Lee, Yoon Chul Jung, Dong Ok Jeon, Hyo Jin Cho, Sung Gyu Im, Sun Kyung Jang,
Ho Joon Kang, Mi Jung Kim, Jang Han Lee n
Department of Internal Medicine, Bundang Jesaeng General Hospital, Sungnam, KoreaArticle history:
Received 15 May 2013
Received in revised form
19 August 2013
Accepted 10 September 2013
Available online 21 November 2013
Keywords:
Chronic kidney disease
Diabetic complications
Diabetic foot
Lower extremity amputations32/$ - see front matter & 2013. The Korea
(http://creativecommons.org/licenses/by-n
x.doi.org/10.1016/j.krcp.2013.10.001
sponding author. Division of Nephrolog
l Medicine, Bundang Jesaeng General H
n-dong, Bundang-gu, Sungnam-si, Gyu
address: idmugss@dmc.or.kr (JH Lee).A b s t r a c t
Background: Diabetic patients are predisposed to foot infections because of vascular
insufﬁciency and peripheral neuropathy. Diabetic foot infection is a common cause of
mortality and lower extremity amputations (LEAs) in patients with chronic kidney
disease (CKD). We evaluated the risk factors for mortality and LEAs in patients with
stage 3 CKD or higher with diabetic foot infections.
Methods: We retrospectively evaluated a cohort of 105 CKD patients with diabetic
foot infections between July 1998 and December 2011. We reviewed their demo-
graphic characteristics and laboratory parameters to evaluate the risk factors for
mortality and amputations at 24 weeks after diagnosis of a diabetic foot infection.
Results: The mortality of the 105 enrolled CKD patients was 21% at 24 weeks after the
diagnosis of a diabetic foot infection. Cox proportional regression analyses revealed that
age 60 years or older [odds ratio (OR) 3.03, 95% conﬁdence interval (CI) = 1.02-9.02, P =
0.047] and initial serum C-reactive protein (CRP) level ≥ 3 mg/dL (OR 3.97, 95% CI = 1.17-
13.43, P = 0.027) were independent risk factors for mortality at 24 weeks. Twenty-four
patients (23%) underwent LEAs. On Cox proportional regression analyses, peripheral
vascular disease (OR¼4.49, 95% CI¼1.98–10.17, P¼0.01) and cerebrovascular accident
(OR 2.42, 95% CI¼1.09–5.39, P¼0.03) were independently associated with LEAs.
Conclusion: This study showed that age and serum CRP level, were independent risk
factors for mortality at 24 weeks in patients with stage 3–5 CKD with diabetic foot
infections. Peripheral vascular disease and cerebrovascular accident were signiﬁcantly
associated with LEAs.
& 2013. The Korean Society of Nephrology. Published by Elsevier. This is an open
access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
Diabetic foot ulceration is one of the main causes of
morbidity and mortality that leads to nontraumatic lowern Society of Nephrology. Publi
c-nd/4.0/).
y, Department of
ospital. 255-2
ngki-do 463–774, Korea.extremity amputations (LEAs) [1,2]. Foot ulcers can become
life-threatening when complicated by infection and might
result in amputation when lesions do not heal [2]. Diabetic
patients are predisposed to foot ulcers and infections because
of impaired immunity, vascular insufﬁciency, and peripheral
neuropathy [1,2]. The annual incidence of diabetic foot ulcers
is between 1.5% and 4% [3]. Diabetic patients have at least a 10-
fold greater risk of hospitalization for foot infections compared
with individuals without diabetes [1]. Nontraumatic LEAs are
at least 15 times more prevalent in those with diabetes than inshed by Elsevier. This is an open access article under the CC BY-NC-ND
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rate after LEAs is up to 50% [5], and the mortality risk
is higher for diabetic patients compared with nondiabetic
patients [6].
Chronic kidney disease (CKD) has been associated with
diabetic foot ulceration and LEAs [3]. Foot complications are
encountered more than 2-fold in diabetic patients with CKD,
and the rate of LEAs is 6.5–10 times greater in comparison to
the general diabetic population [7]. One-year survival was 71%
among diabetic patients on dialysis with foot lesions compared
with 94% among their counterparts without renal impairment
[8]. Even CKD stage 3 was independently associated with
higher mortality within 30 days after nontraumatic LEAs [9].
There are only a few studies on the risk factors for mortality
and amputations in patients with stage 3–5 CKD with diabetic
foot infections. Therefore, the purpose of this study was to
identify risk factors for mortality and LEAs within 24 weeks
after the diagnosis of diabetic foot infection in patients with
CKD stage 3–5.Table 1. Baseline demographics and characteristics of patients
(N¼105)
Variable Value
Demographics
Male 62 (59)
Age (y) 61.6713.5
60 y or older group 62 (59)
Medical conditions
HTN 82 (78)
PVD 18 (17)
CVA 33 (31)
CVD 20 (19)
SIRS 21 (20)
Peripheral neuropathy 41 (39)
Diabetic retinopathy 55 (52)
Smoking 32 (31)
CKD stage
Stage 3 18 (17)
Stage 4 10 (10)
Stage 5 77 (73)
Laboratory data
White blood cell (/mm3) 12,502.178230.5
White blood cell (/mm3; 2 wks later) 10,361.474921.9
White blood cell (/mm3; 4 wks later) 9188.673694.2
Hemoglobin (g/dL) 9.671.9
BUN (mg/dL) 45.8723.7
Cr (mg/dL) 4.672.9
CRP (mg/dL) 7.677.2
CRP (mg/dL; 2 wks later) 4.875.2
CRP (mg/dL; 4 wks later) 3.974.6
HbA1c (%) 7.772.9
Glucose(mg/dL) 2197137.9
Cholesterol (mg/dL) 145.5747.7
Albumin (g/dL) 3.370.5
Ca (mg/dL) 8.770.9
P (mg/dL) 4.171.6
Ca P (mg2/dL2) 35.4714.3
Data are presented as mean7SD or n (%).
BUN, blood urea nitrogen; Ca, calcium; CKD, chronic kidney disease; Cr,
creatinine; CRP, C-reactive protein; CVA, cerebrovascular accident; CVD,
cardiovascular disease; HbA1c, hemoglobin A1c; HTN, hypertension; P,
phosphorus; PVD, peripheral vascular disease; SD, standard deviation;
SIRS, systemic inﬂammatory response syndrome.Methods
Study population
This study investigated CKD patients with an estimated
glomerular ﬁltration rate (eGFR) of o60 mL/min/1.73 m2 and
diabetic foot infections who were attending Bundang Jesaeng
General Hospital (Sungnam, South Korea) from July 1998 to
December 2011. We identiﬁed and enrolled 105 patients, all of
whom had been followed for 24 weeks.
Data collection
The clinical characteristics at diagnosis of a diabetic foot
infection in patients with CKD stage 3–5 were collected. The
potential clinical risk factors were recorded, including demo-
graphic features (age and sex) and the presence of medical
conditions such as hypertension (HTN), peripheral vascular
disease (PVD), cerebrovascular accident (CVA), cardiovascular
disease (CVD), systemic inﬂammatory response syndrome,
peripheral neuropathy, diabetic retinopathy, and smoking.
Laboratory data were also reviewed including blood urea
nitrogen, creatinine, white blood cell (WBC), hemoglobin,
C-reactive protein (CRP), hemoglobin A1c, glucose, total cho-
lesterol, albumin, calcium, and phosphorus.
Assessment of renal function
Renal function was calculated using the simpliﬁed Modiﬁ-
cation of Diet in Renal Disease (MDRD) equation and categor-
ized according to CKD stage in compliance with the National
Kidney Foundation Kidney Disease Outcomes Quality Initiative
(K/DOQI) guidelines [10]. Patients with CKD were indicated as
those who had stage 3, 4, or 5 CKD with an eGFR less than
60 mL/min/1.73 m2.
Deﬁnition
Diabetes mellitus was deﬁned by physician's diagnosis or
current treatment with hypoglycemic medication. PVD was
deﬁned as a narrowing of blood vessels documented on angio-
graphy or computerized tomographic angiography. Peripheralneuropathy was assessed by vibratory, monoﬁlament, muscle
strength, and tendon reﬂex testing. The deﬁnition of diabetic foot
infection was foot ulceration, soft tissue infection, or bone
infection with elevated serum CRP level [1]. LEA was deﬁned as
a surgical removal of part of a lower extremity. CVD was deﬁned
as a history of acute coronary syndrome, or according to previous
coronary angiographic ﬁndings (Z 50% stenosis in one or more
of the coronary arteries) [11]. A history of CVA was conﬁrmed by
computed tomographic scans or magnetic resonance images.
HTN was diagnosed as a systolic blood pressure of 140 mmHg or
more, or a diastolic blood pressure of 90 mmHg or more on three
separate visits, or when the enrolled patients received antihy-
pertensive agents. Patients were considered to have systemic
inﬂammatory response syndrome if they had two or more of the
following criteria: body temperature o36 1C or 438 1C, heart
rate 490 beats/min, tachypnea with 420 breaths/min or an
arterial partial pressure of carbon dioxide o32 mmHg, WBC
count o4000 cells/mm3 or 412,000 cells/mm3 or the presence
of 410% immature neutrophils (band forms).Statistical analysis
The clinical characteristics of the patients were presented as
means7standard deviations for continuous variables or as
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assessed using the Chi-square test, and continuous variables
were compared with independent t tests. The Kaplan–Meier
method with the log-rank test and multivariate Cox propor-
tional regression analyses were performed to identify the
factors independently associated with mortality and amputa-
tions. Variables with Po0.05 on univariate analysis were
included in the multivariate Cox proportional model, and odds
ratios (OR) and 95% conﬁdence intervals (CI) were calculated.
The receiver operating characteristic curve analysis was used to
estimate the area under the curve of the model predicting
the mortality of serum CRP level. Risk estimates were pre-
sented as OR with 95% CI, and Po0.05 were considered
statistically signiﬁcant. Statistical analyses were performed
using the SPSS statistical software (Version 16.0.1; SPSS Inc.,
Chicago, IL, USA).Results
We assessed a group of 105 CKD stage 3–5 patients (62
males, 59%) with diabetic foot infections with a mean age of
61.6713.5 years. Based on the patients’ medical records, the
prevalence of HTN was 78%, and 18 patients (17%) had PVD.
A total of 33 patients (31%) had a history of CVA and 20
patients (19%) had CVD.
Of the enrolled patients, 18 had CKD stage 3, 10 patients had
stage 4, and 77 patients (73%) had stage 5. A total of 73
patients (70%) were receiving renal replacement therapy.Table 2. Comparison of clinical characteristics between nonsurvival an
Characteristic Nonsurviva
(n ¼ 22)
Male sex 12 (55)
Age (y) 66.4712.9
60 y or older 18 (82)
HTN 18 (82)
PVD 6 (27)
CVD 8 (36)
Stage 5 CKD 20 (91)
CRP Z3 mg/dL 19 (86)
Peripheral neuropathy 7 (32)
Diabetic retinopathy 11 (50)
SIRS 6 (27)
Smoking 8 (35)
Amputation 6 (27)
White blood cell (/mm3) 12,490.97570
White blood cell (/mm3; 2 wks later) 12,80576923
White blood cell (/mm3; 4 wks later) 11,517.67502
Hemoglobin (g/dL) 9.171.7
BUN (mg/dL) 51.5723
Cr (mg/dL) 4.471.8
CRP (mg/dL) 10.777.1
CRP (mg/dL; 2 wks later) 7.576.1
CRP (mg/dL; 4 wks later) 7.475.5
HbA1C 6.772.6
Glucose (mg/dL) 215.6792.6
Cholesterol (mg/dL) 131.8743.2
Albumin (g/dL) 3.270.5
Ca (mg/dL) 8.870.9
P (mg/dL) 4.171.3
CaP (mg2/dL2) 35.9711.9
Data are presented as mean7SD or n (%).
BUN, blood urea nitrogen; Ca, calcium; CKD, chronic kidney disease; Cr, cr
cardiovascular disease; HbA1c, hemoglobin A1c; HTN, hypertension; P, phos
systemic inﬂammatory response syndrome.Hemodialysis was used in 62 patients (85%), whereas the
remaining patients were treated with peritoneal dialysis. The
mean laboratory values included an initial plasma CRP of
7.677.2 mg/dL and a hemoglobin A1c of 7.772.9%. The mean
baseline plasma albumin was 3.370.5 g/dL, whereas serum
calcium and phosphate levels were 8.770.9 mg/dL and
4.171.6 mg/dL, respectively (Table 1).
The overall mortality was 21% (22 patients), and the mean
duration from diagnosis until death was 8.776.5 weeks
(range, 1–20 weeks). The leading cause of death was CVD (14
patients, 64%), followed by infection (8 patients, 36%), includ-
ing pneumonia (3 patients), sepsis secondary to foot infection
(4 patients), and catheter-related infection (1 patient). A total
of 24 patients (23%) underwent LEAs during the study period.
The median time from diagnosis to amputation was 574.7
weeks (range, 1–19 weeks).
On univariate analysis, the proportion of patients aged 60
years or older was higher in the nonsurviving group compared
with the survivors. The prevalence of CVD and CKD stage
5 were higher in the nonsurviving group of patients. Initial and
follow up CRP levels and WBC counts at 4 weeks were higher
in the nonsurviving group of patients. There are more patients
with initial serum CRPZ3mg/dL in the nonsurviving group
than survivors (Table 2). Additionally, the prevalence rates of
PVD and CVA were higher in the group of amputees compared
with the nonamputees (Table 3).
We computed the area under the receiver operating character-
istic associated with mortality-prediction models based on serum
CRP levels. In this analysis, the initial serum CRP level was shownd survival groups
l Survival
(n ¼ 83)
P
50 (60) 0.63
60.4713.4 0.06
44 (53) 0.02
64 (77) 0.77
12 (15) 0.47
12 (15) 0.02
57 (69) 0.04
48 (59) 0.02
34 (4) 0.47
44 (53) 0.81
15 (18) 0.37
24 (29) 0.60
18 (22) 0.57
9.2 12,505.178807.2 0.99
.5 9585.773848.7 0.06
4.9 8441.572827.9 0.03
9.771.9 0.14
44.3723.8 0.20
4.773.1 0.65
6.877.1 0.03
3.874.5 0.01
2.673.5 0.01
7.872.9 0.11
219.97148 0.86
149.1748.4 0.11
3.370.6 0.13
8.670.9 0.36
4.171.7 0.91
35.3714.9 0.85
eatinine; CRP, C-reactive protein; CVA, cerebrovascular accident; CVD,
phorus; PVD, peripheral vascular disease; SD, standard deviation; SIRS,
Table 4. Multivariate Cox proportional regression analysis of risk
factors associated with mortality
Variable P Odds ratio 95% CI
60 y or older 0.047 3.03 1.02–9.02
CRP Z3 mg/dL 0.027 3.97 1.17–13.43
CVD 0.062 2.31 0.96–5.55
CI, conﬁdence interval; CRP, C-reactive protein; CVD, cardiovascular
disease.
Table 3. Comparison of clinical characteristics between amputees and nonamputees
Characteristic Amputees
(n ¼ 24)
Nonamputees
(n ¼ 81)
P
Male sex 14 (58.3) 48 (59.3) 0.93
Age (y) 64.8711.4 60.7713.9 0.18
60 y or older 17 (70.8) 45 (55.6) 0.23
HTN 20 (83.3) 62 (76.5) 0.58
PVD 10 (41.7) 8 (9.9) 0.001
CVA 12 (50.0) 21 (25.9) 0.026
CVD 4 (16.7) 16 (19.8) 0.73
Stage 5 CKD 17 (70.8) 60 (74.1) 0.79
CRP ≥3 mg/dL 18 (75) 49 (62) 0.33
Peripheral neuropathy 6 (25) 35 (43.2) 0.15
Diabetic retinopathy 10 (41.7) 45 (55.6) 0.25
SIRS 6 (25) 15 (18.5) 0.56
Smoking 9(37.5) 23 (28.4) 0.45
White blood cell (/mm3) 16,500712,310.2 11,317.576187 0.06
White blood cell (/mm3; 2 wks later) 11,245.575050.8 10,042.674877.4 0.32
White blood cell (/mm3; 4 wks later) 9077.373611.5 9239.673768.2 0.86
Hemoglobin (g/dL) 9.971.1 9.572.0 0.16
BUN (mg/dL) 43.5720.3 46.5724.7 0.59
Cr (mg/dL) 4.572.8 4.772.9 0.80
CRP (mg/dL) 8.978.0 7.377.0 0.33
CRP (mg/dL; 2 wks later) 5.775.1 4.475.3 0.33
CRP (mg/dL; 4 wks later) 4.574.9 3.574.4 0.42
HbA1C 7.273.0 7.772.9 0.51
Glucose (mg/dL) 189.87112.4 227.77144 0.23
Cholesterol (mg/dL) 135.3739.6 148.5749.6 0.23
Albumin (g/dL) 3.470.5 3.370.6 0.23
Ca (mg/dL) 8.971.1 8.670.9 0.24
P (mg/dL) 4.271.6 4.171.6 0.83
Ca P (mg2/dL2) 36.5713.2 35.1714.7 0.69
Data are presented as mean7SD or n (%).
BUN, blood urea nitrogen; Ca, calcium; CKD, chronic kidney disease; Cr, creatinine; CRP, C-reactive protein; CVA, cerebrovascular accident; CVD,
cardiovascular disease; HbA1c, hemoglobin A1c; HTN, hypertension; P, phosphorus; PVD, peripheral vascular disease; SD, standard deviation; SIRS,
systemic inﬂammatory response syndrome.
Table 5. Multivariate Cox proportional regression analysis of risk
factors associated with amputations
Variable P Odds ratio 95% CI
PVD 0.010 4.49 1.98–10.17
CVA 0.030 2.42 1.09–5.39
CI, conﬁdence interval; CVA, cerebrovascular accident; PVD, peripheral
vascular disease.
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0.678 (95% CI¼0.560–0.797, P¼0.01), and the best predictive
value was 3.26 mg/dL (sensitivity 47%, speciﬁcity 86%). The
Kaplan–Meier survival curves demonstrated that high initial
serum CRP (Z3.0 mg/dL) was associated with higher mortality
than low initial serum CRP (o 3.0 mg/dL; log rank 5.14, P¼0.02).
The multivariate Cox proportional analysis revealed that
age Z60 years (OR 3.03, 95% CI 1.02-9.02, P = 0.047) andinitial serum CRP ≥ 3 mg/dL (OR 3.97, 95% CI 1.17-13.43, P =
0.027) were independently associated with mortality within
24 weeks of the diagnosis of diabetic foot infection (Table 4).
To determine the independent risk factors for LEAs, we
performed a series of multivariable Cox proportional analyses.
Consequently, we found that PVD (OR 4.49, 95% CI 1.98–10.17,
P¼0.01) and CVA (OR 2.42, 95% CI 1.09–5.39, P¼0.03) were
signiﬁcantly associated with LEAs (Table 5).
In our study, contrast-induced nephropathy occurred in 12
patients after the administration of a contrast medium. How-
ever, the prevalence of contrast-induced nephropathy was not
statistically signiﬁcantly associated with mortality.Discussion
This study showed that in patients with stage 3–5 CKD with
diabetic foot infections, mortality was associated with old age,
serum CRP level after adjusting for potential confounders. We also
found that PVD and CVA were independent risk factors for LEAs.
Old age is a risk factor for CKD and CVD. Shlipak et al [12]
showed that elderly patients with mild to moderate CKD had a
substantial risk for cardiovascular mortality. The 1-year mor-
tality of elderly patients with moderate CKD after myocardial
infarction is nearly 3-fold compared to those with normal
renal function [13].
Our study showed that patients with CVD had a tendency
to higher mortality. Patients with CKD had a signiﬁcant
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cardiogenic shock after myocardial infarction [14]. Death from
cardiac causes is 10–20 times more common in CKD [15].
Serum CRP level is elevated in patients with CKD [16] and is
an independent predictor of cardiovascular mortality in this
population [17]. Serum CRP level, a circulating marker of
inﬂammation, is closely linked to CVD [18]. Recent data from
the MDRD study showed that high serum CRP was an
independent risk factor for all-cause mortality in patients with
CKD stages 3 and 4 [19]. Zimmerman et al [20] showed that
high serum CRP was an independent predictor of 2-year all-
cause mortality in 280 stable hemodialysis patients. Our
current results showed that initial serum CRP Z3.0 mg/dL
was a strong predictor of 24-week mortality in CKD stage 3–5
patients with diabetic foot infections. This ﬁnding may have
implications for early risk identiﬁcation and for targeted
interventions to reduce the risk of mortality in high-risk
patients.
We found that PVD was independently associated with an
increased risk of LEAs. Some previous studies suggest that the
risk factors of LEAs are PVD, peripheral neuropathy, retino-
pathy, minor trauma, infection, impaired wound healing, and
limited joint mobility [21,22]. PVD is a major component factor
for LEAs [23]. Insufﬁcient blood supply is an important con-
tributor to foot ulceration and plays a signiﬁcant role in the
delayed healing of an ulcer once it developed. American
Diabetes Association emphasized the need for the prevention
of PVD in patients with CKD stage 3 or higher with diabetic
foot infections.
The result of our study is consistent with those of previous
studies that reported CVA as a signiﬁcant risk factor for
LEAs [24,25]. The kidney and the brain share unique suscept-
ibilities to vascular injury. Therefore, some risk factors for
atherosclerosis such as HTN, diabetes, and dyslipidemia may
result in similar vascular injuries in both organs [26]. The
mechanisms involved in this association may be related to
traditional and nontraditional risk factors, such as endothelial
dysfunction, oxidative stress, inﬂammation, hyperhomocystei-
nemia, and thrombogenic factors [27,28]. All of these factors
may play a role in accelerated atherosclerosis in the arteries of
the kidney and the brain.
The current study has several limitations. First, this study
has a retrospective, observational, single-center design. Sec-
ond, the use of statins and angiotensin-converting enzyme
inhibitors may be associated with lower serum CRP levels in
patients with ischemic heart disease, stroke, or CKD [29,30].
Therefore, our study might have underestimated the serum
CRP level.
Our study result suggests that an initial serum CRP Z3 mg/dL
may predict mortality in patients with stage 3–5 CKD with
diabetic foot infections.Conﬂicts of interest
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